Fort Lee, NJ -- (SBWIRE) -- 11/30/2017 -- Herborium® Group, Inc. (OTCMKTS:HBRM), www.Herborium.com, a Botanical Therapeutics® Company and the provider of unique all botanical medicinal products (Botanical Therapeutics®) targeting dermatological issues such as acne, and other health and wellness concerns, announced today that its 2017 Black Friday and Cyber Monday e commerce sales for its leading dermatological product, AcnEase, grew 115% over the same sales event in 2016.
The social media campaigns associated with Black Friday and Cyber Monday more than doubled sales in the USA and Canada. Additionally, Herborium websites experienced a substantial increase in international traffic from first official Black Friday in France and the second one in Great Britain. The Hut Group LLC, Herborium's UK distributor launched its first Black Friday/Cyber Monday promotional campaign which the Company expects to result in increased wholesale orders.
Herborium's AcnEase® product has a track record for repeat sales of over 55% for up to 3 months following an initial order and over 35% for 4 and more months following an initial order. The Company anticipates this combined with the sales growth from Black Friday/Cyber Monday to increase the number of new customers and therefore continued sales appreciation going forward. Furthermore, this growth is expected to augment product brand recognition and future new customer acquisition as well.
The Company has also seen an increase in interest and demand for the Rejuvel 3D Skin Renewal Cream for acne scars. Herborium has been test marketing the Rejuvel product as an add-on to its signature product (https://www.acnease.com/products/rejuvel-3d.htm). As a result of the positive test marketing, the Company has launched an international marketing campaign and begun full distribution of the product throughout its network.
The Company will continue its marketing push throughout the holiday season by adding a special series of events targeting the rapidly growing markets for AcnEase in Europe, Australia and Latin America.
To date Herborium's 2017 sales performance surpassed 2016 sales by 16.5%, confirming management's expectations for record 2017 sales results.
Dr. Agnes P. Olszewski, CEO and Chairwoman of Herborium Group, stated, "We expect a continued increase of sales through the end of the 4th quarter of 2017 and into 2018 given the new initiatives that have been put in place." Dr. Agnes P. Olszewski, continued "The Company's growth in the USA and abroad continues and Herborium will announce shortly new sales initiatives for 2018 to further support this growth. We look forward to the very strong ending of 2017, and a very successful 2018"
Over 75 million people have acne in the USA. Seventy five percent of all individuals will suffer from acne at some point in their lives. The acne treatment and prevention market is growing while at the same time no new products are emerging and the number of previously used treatments is dwindling or restricted because of recognized health concerns. (Accutane, antibiotics, oral contraceptives as examples) The average age of the acne sufferer has increased during the past decade from 21 years old to 26 years old, making adult acne an epidemic.
AcnEase® is a systemic, proprietary all herbal product that contains no chemicals and has demonstrated up to 96% efficacy in eliminating and preventing acne breakouts with no adverse side effects. From a regulatory perspective, AcnEase is considered a nutraceutical allowing AcnEase to take advantage of the rapid global growth of the nutraceutical market. For instance, the global nutraceutical market is valued at around USD 250 billion in 2016 and is expected to reach around USD 385 billion by 2021, at a CAGR of 7.5% from 2016 to 2021. US nutraceutical market has dominated this growth accounting for ~ 36% of this growth.
About Herborium Group, Inc.
Herborium Group, Inc. is a botanical therapeutics® company that develops, licenses and markets proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company's business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium has secured a pipeline of botanical ingredients based products in the areas of dermatological needs, wellness and energy, prostate health, women's health and selected sexual disorders Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce.
For more information, please visit www.herborium.com, www.acnease.com, www.acnease.fr and www.acneasesp.com.
Safe Harbor Statement
This release contains forward-looking statements with respect to the results of operations and business of Herborium Group, Inc., which involves risks and uncertainties. The Company's actual future results could materially differ from those discussed. The Company intends that such statements about the Company's future expectations, including future revenues and earnings, and all other forward looking statements be subject to the "Safe Harbors" provision of the Private Securities Litigation Reform Act of 1995.
Herborium Group, Inc.
Source: Uptick Newswire